Tissue Regenix Group PLC 2023 LTIP Grant (6727A)
23 Janvier 2024 - 6:24PM
UK Regulatory
TIDMTRX
RNS Number : 6727A
Tissue Regenix Group PLC
23 January 2024
Tissue Regenix Group plc
("Tissue Regenix" or "the Group")
2023 LTIP Grant
Tissue Regenix (AIM: TRX), the regenerative medical devices
company, announces that Daniel Lee, Chief Executive Officer, and
David Cocke, Chief Financial Officer, were each granted an award of
restricted share units ("RSUs") with respect to ordinary shares in
the capital of the Company ("Ordinary Shares") on 21 March 2023,
under the Company's existing Long-Term Incentive Plan, following
the publication of its 2022 results.
Daniel Lee was awarded 19,807,390 RSUs (subsequently reduced to
198,073 RSUs following the Company's share consolidation that
became effective on 28 April 2023) and David Cocke has been awarded
15,367,803 RSUs (subsequently reduced to 153,678 RSUs), where each
RSU that vests shall represent the right to receive payment of one
Ordinary Share. The exercise price of the RSUs was 0.1p per
Ordinary Share (subsequently adjusted to 10p). The RSUs are subject
to continued service over a period of three years and satisfaction
of customary performance conditions relating to growth in total
shareholder return, annual revenue targets, annual profitability
targets and personal performance targets, further details of which
will be set out in the Company's 2023 Annual Report.
Following the grant of these options, Daniel Lee and David Cocke
hold options over a total of 756,897 and 514,002 RSUs respectively
representing 1.1% and 0.7% of the current issued share capital
respectively.
For more information:
Tissue Regenix Group plc www.tissueregenix.com
David Cocke, Chief Financial Officer via Walbrook PR
Cavendish Capital Markets Limited (Nominated
Adviser and Broker)
Emily Watts/Geoff Nash/George Dollemore - Corporate
Finance
Nigel Birks/Harriet Ward - ECM
Walbrook PR (Financial PR and IR) Tel: +44 (0)20 7933 8780
Charlotte Edgar / Alice Woodings TissueRegenix@walbrookpr.com
About Tissue Regenix ( www.tissueregenix.com )
Tissue Regenix is a leading medical devices company in the field
of regenerative medicine. The company's patented decellularisation
('dCELL(R)') technology removes DNA and other cellular material
from animal and human soft tissue leaving an acellular tissue
scaffold which is not rejected by the patient's body and can then
be used to repair diseased or worn-out body parts. Current
applications address many critical clinical needs such as sports
medicine, heart valve replacement and wound care.
In August 2017 Tissue Regenix acquired CellRight
Technologies(R), a biotech company that specializes in regenerative
medicine and is dedicated to the development of innovative
osteoinductive and soft tissue scaffolds that enhance healing
opportunities of defects created by trauma and disease. CellRight's
human osteobiologics may be used in spine, trauma, general
orthopaedic, foot & ankle, dental, and sports medicine surgical
procedures.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities ("PDMRs") and persons
closely associated ("PCA") with them.
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Daniel Lee
--------------------- -------------------------------------------
2 Reason for the notification
------------------------------------------------------------------
a) Position/status CEO
--------------------- -------------------------------------------
b) Initial notification Initial notification
/Amendment
--------------------- -------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
------------------------------------------------------------------
a) Name Tissue Regenix Group plc
--------------------- -------------------------------------------
b) LEI 213800PNOD5UHQUFJI36
--------------------- -------------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place where
transactions have been conducted
------------------------------------------------------------------
a) Description Restricted share units ("RSUs") with
of the financial respect to ordinary shares in the capital
instrument, of the Company of 0.1p
type of instrument
--------------------- -------------------------------------------
b) Identification GB00B5SGVL29
code
--------------------- -------------------------------------------
c) Nature of the Issue of options
transaction
--------------------- -------------------------------------------
d) Price(s) and Volume(s):
volume(s) 19,807,390 RSUs
Price: 0.1 pence per RSU
--------------------- -------------------------------------------
d) Aggregated
information 19,807,390
- Aggregated GBP19,807.39
volume
- Price
--------------------- -------------------------------------------
e) Date of the 21 March 2023
transactions
--------------------- -------------------------------------------
f) Place of the Outside of a trading venue
transaction
--------------------- -------------------------------------------
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name David Cocke
--------------------- -------------------------------------------
2 Reason for the notification
------------------------------------------------------------------
a) Position/status CFO
--------------------- -------------------------------------------
b) Initial notification Initial notification
/Amendment
--------------------- -------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
------------------------------------------------------------------
a) Name Tissue Regenix Group plc
--------------------- -------------------------------------------
b) LEI 213800PNOD5UHQUFJI36
--------------------- -------------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place where
transactions have been conducted
------------------------------------------------------------------
a) Description Restricted share units ("RSUs") with
of the financial respect to ordinary shares in the capital
instrument, of the Company of 0.1p
type of instrument
--------------------- -------------------------------------------
b) Identification GB00B5SGVL29
code
--------------------- -------------------------------------------
c) Nature of the Issue of options
transaction
--------------------- -------------------------------------------
d) Price(s) and Volume(s):
volume(s) 15,367,803 RSUs
Price: 0.1 pence per RSU
--------------------- -------------------------------------------
d) Aggregated
information 15,367,803
- Aggregated GBP15,367.80
volume
- Price
--------------------- -------------------------------------------
e) Date of the 21 March 2023
transactions
--------------------- -------------------------------------------
f) Place of the Outside of a trading venue
transaction
--------------------- -------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHDXLFLZFLLBBL
(END) Dow Jones Newswires
January 23, 2024 12:24 ET (17:24 GMT)
Tissue Regenix (LSE:TRX)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Tissue Regenix (LSE:TRX)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024